Cofactor Genomics Commences First Predictive Immune Modeling Clinical Trial to Bridge Precision Medicine Gap for Immunotherapy
SAN FRANCISCO, Calif. – April 13, 2021 – Cofactor Genomics, the company bridging the precision medicine gap, today announced commencement of the first multicenter clinical trial of its OncoPrismTM diagnostic assay, using the company’s patented approach to generating multidimen...
New Data Published from Women & Infants Hospital Demonstrate Utility of Predictive Immune Modeling in Ovarian Cancer
PROVIDENCE, R.I. – March 8, 2021 – Cofactor Genomics, the company bridging the precision medicine gap, announced today new data published in Frontiers in Oncology1 by Women & Infants Hospital of Rhode Island. The data highlight the utility of Cofactor’s Predictive Immune Model...
UCSD Partners with Cofactor Genomics to Improve Patient Outcomes in Metastatic Head and Neck Cancer
SAN DIEGO, Calif.– SEPTEMBER 15, 2020 – Physicians at the University of California, San Diego (UCSD) School of Medicine and Cofactor Genomics, the company bridging the precision medicine gap, today announced a partnership aimed at improving a physician’s ability to predict tum...